期刊文献+

不同尿素氮水平尿毒血清对人脐静脉内皮细胞的影响

Effect of Different Blood Urea Nitrogen Level Uremic Serum on Human Umbilical Vein Endothelial Cells
原文传递
导出
摘要 目的:观察不同BUN水平尿毒血清对体外培养人脐静脉内皮细胞(HUVEC)的影响,并探讨尿毒症患者动脉粥样硬化发病的可能机制。方法:比色法测定HUVEC上清液NO、MDA的水平;免疫细胞化学法测定胞浆iNOS表达;酶联免疫吸附法(ELISA)测定上清液iNOS蛋白水平。结果:尿毒血清各组均可上调HUVEC的MDA生成,且以BUN≥50mmol/L的尿毒血清组对MDA上调最明显(P<0.01);尿毒血清各组可下调HUVEC的NO生成,呈BUN浓度依赖性关系(P<0.01);尿毒血清各组可激活HUVEC的iNOS,诱导细胞生成大量NO,但随着BUN水平的升高,NO、iNOS呈下降趋势,BUN≥50mmol/L尿毒血清组下降显著(P<0.01)。结论:尿毒血清对HUVEC有毒性作用,呈BUN浓度依赖性关系,尤其是BUN≥50mmol/L时,细胞损伤更为加重。 Objective: To observe the effect of different blood urea nitrogen (BUN) level uremic serum on human umbilical vein endothelial cells (HUVEC) cultured in vitro, and investigate the possible mechanism about atherosclerosis in uremia patients. Methods: The content of NO and MDA were detected by colorimetry, and the expression ofiNOS was detected by immunocytochemical staining in HUVEC cytoplasm. The protein expression of iNOS in supemate was detected by enzyme-linked immunosorbent assay (ELISA). Results: The MDA capacity with uremic serum in HUVEC was significantly higher than that of control group, and the group of BUN≥ 50 mmol/L uremic serum showed the greatest upregulation (P〈0.01). The level of NO in uremic serum media was significantly lower than that of the control, with a BUN concentration-dependence (P〈0.01). The expression ofiNOS in HUVEC was activated by uremic serum and induced a lot of NO. However, with BUN level increased, the level of NO and iNOS were decreased, with the most significant decrease in group of BUN ≥50 mmol/L uremic serum (P〈0.01). Conclusion: Uremic serum can impair HUVEC in a BUN concentration-dependent manner, and BUN ≥ 50 mmol/L uremic serum showed the worst effect.
出处 《现代生物医学进展》 CAS 2009年第8期1443-1446,共4页 Progress in Modern Biomedicine
关键词 尿毒血清 内皮细胞 一氧化氮 丙二醛 诱导型一氧化氮合酶 Uremic serum Human umbilical vein endothelial cells (HUVEC) Nitric oxide (NO) Malondialdehyde (MDA) In-ducible nitric oxide synthase (iNOS)
  • 相关文献

参考文献1

二级参考文献16

  • 1侯凡凡.慢性肾脏病的心血管并发症[J].中华心血管病杂志,2004,32:16-16.
  • 2何长民 张训 见:何长民 张训主编.前言[A].见:何长民,张训主编.肾脏替代治疗学[C].上海:上海科学技术文献出版社,1999.2..
  • 3Locatelli F, Pozzoni P, Tentori F, et al. Epidemiology of cardiovascular risk in patients with chronic kidney disease. Nephrol Dial Transplant, 2003,18 Suppl 7:2-9.
  • 4Muntner P, He J, Hamm L, et al. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol, 2002,13:745-753.
  • 5Manjunath G, Tighiouart H, Ibrahim H, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol, 2003,41:47-55.
  • 6Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int, 1995,47:186-192.
  • 7Sarnak MJ, Levey AS, Schoolwerth AC,et al. Kidney disease as a risk factor for development of cardiovascular disease. A statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation, 2003,108:2154-2169.
  • 8Foley RN, Herzog CA, Collins AJ. Smoking and cardiovascular outcomes in dialysis patients: the United States Renal Data System Wave 2 Study. Kidney Int, 2003,63:1462-1467.
  • 9Wong JS, Rort FK, Hulbert-Shearon TE, et al. Survival advantage in Asian American end-stage renal disease patients. Kidney Int, 1999,55:2515-2523.
  • 10Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis, 1998,32:s112-s119.

共引文献182

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部